Drug Profile
Adalimumab biosimilar - PlantPraxis
Alternative Names: AMABLatest Information Update: 29 Mar 2023
Price :
$50
*
At a glance
- Originator PharmaPraxis; PlantForm - PharmaPraxis (JV)
- Developer PharmaPraxis
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Crohn's disease; Rheumatoid arthritis
Most Recent Events
- 29 Mar 2023 Discontinued - Preclinical for Crohn's disease in Brazil (SC)
- 29 Mar 2023 Discontinued - Preclinical for Rheumatoid arthritis in Brazil (SC)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Crohn's-disease in Brazil (SC, Injection)